CRD-4730
Sponsors
Cardurion Pharmaceuticals Inc., Cardurion Pharmaceuticals, Inc.
Conditions
CPVT1Catecholaminergic Polymorphic Ventricular TachycardiaCatecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Heart Defects, CongenitalHeart DiseasesHeart Failure With Reduced Ejection Fraction (HFrEF)Ventricular Tachycardiaheart failure
Phase 2
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
TerminatedNCT06005428
Start: 2023-11-07End: 2025-05-31Updated: 2026-05-27
A PHASE 2A, INVESTIGATOR AND SUBJECT BLINDED, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA
CompletedCTIS2022-502845-83-00
Start: 2024-04-15End: 2025-05-31Target: 5Updated: 2025-03-21
A Phase 2 Study of CRD-4730 in CPVT
RecruitingNCT06658899
Start: 2025-12-01End: 2027-04-01Target: 12Updated: 2026-07-09
A PHASE 2, DOUBLE-BLIND, REPEAT-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA
RecruitingCTIS2024-515564-32-00
Start: 2025-11-20Target: 6Updated: 2025-11-07
A Trial of CRD-4730 in HFrEF
RecruitingNCT07750873
Start: 2026-07-15End: 2028-09-01Target: 525Updated: 2026-08-06
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)
(CALIBRATE-HF)
Not yet recruitingCTIS2025-525033-31-00
Target: 102Updated: 2026-08-14